• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Results of a phase I study to determine the maximum tolerated dose of capecitabine when given concurrently with radical radiotherapy in the treatment of squamous cell carcinoma of the head and neck.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Sykes, Andrew J
    Slevin, Nicholas J
    MacDougall, Robert H
    Ironside, Janet A D
    Mais, Kathleen L
    Affiliation
    Christie Hospital, Wilmslow Road, Manchester M20 4BX, UK.
    Issue Date
    2004-04
    
    Metadata
    Show full item record
    Abstract
    Capecitabine is preferentially converted to 5-fluorouracil within tumours, exploiting the higher levels of thymidine phosphorylase (TP) found in areas of poor perfusion and hypoxia. In addition radiation leads to up regulation of TP expression. To exploit these advantages of capecitabine as a synchronous chemoradiotherapy agent patients with advanced squamous cell carcinoma of the head and neck were recruited into a phase I non-randomised dose finding study. Capecitabine was given twice daily, 7 days a week at a dose starting at 350 mg/m(2) bid. Radiotherapy using a beam directed technique was prescribed to 55 Gy in 20 fractions over 4 weeks. A total of 24 patients were treated. Dose-limiting toxicity (grade IV mucositis) was reached at a capecitabine dose of 550 mg/m(2) bid. Radiotherapy was completed without delay in all cases. There was no systemic drug related toxicity. Capecitabine offers the prospect of an orally administered drug for use synchronously with radiotherapy, which in doses up to 500 mg/m(2) bid is well tolerated.
    Citation
    Results of a phase I study to determine the maximum tolerated dose of capecitabine when given concurrently with radical radiotherapy in the treatment of squamous cell carcinoma of the head and neck. 2004, 71 (1):81-4 Radiother Oncol
    Journal
    Radiotherapy and Oncology
    URI
    http://hdl.handle.net/10541/78105
    DOI
    10.1016/j.radonc.2004.02.001
    PubMed ID
    15066299
    Type
    Article
    Language
    en
    ISSN
    0167-8140
    ae974a485f413a2113503eed53cd6c53
    10.1016/j.radonc.2004.02.001
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • Phase one dose finding study of capecitabine (Xeloda), radiotherapy and cisplatin in the treatment of locally advanced squamous cervical cancer.
    • Authors: Stokes Z, Symonds P, Habeshaw T, Reed N, Curto J, Joynson C, Chan S
    • Issue date: 2005 Jun
    • Capecitabine-based chemoradiotherapy with adjuvant capecitabine for locally advanced squamous carcinoma of the uterine cervix: phase II results.
    • Authors: Domingo E, Lorvidhaya V, de Los Reyes R, Syortin T, Kamnerdsupaphon P, Lertbutsayanukul C, Vito-Cruz E, Tharavichitkul E, Jin K, Yoshihara M, Cupino N, Lertsanguansinchai P
    • Issue date: 2009 Aug
    • A phase I-II study of postoperative capecitabine-based chemoradiotherapy in gastric cancer.
    • Authors: Jansen EP, Boot H, Saunders MP, Crosby TD, Dubbelman R, Bartelink H, Verheij M, Cats A
    • Issue date: 2007 Dec 1
    • Synchronous chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck using capecitabine: a single-centre, open-label, single-group phase II study.
    • Authors: Jegannathen A, Mais K, Sykes A, Lee L, Yap B, Birzgalis A, Homer J, Ryder WD, Slevin N
    • Issue date: 2011 Mar
    • Simultaneous integrated boost-intensity modulated radiation therapy with concomitant capecitabine and mitomycin C for locally advanced anal carcinoma: a phase 1 study.
    • Authors: Deenen MJ, Dewit L, Boot H, Beijnen JH, Schellens JH, Cats A
    • Issue date: 2013 Apr 1
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.